Clinical outcomes of Β-blocker therapy in cocaine-associated heart failure

López, Persio D.; Akinlonu, Adedoyin; Mene-Afejuku, Tuoyo O; Dumancas, Carissa; Saeed, Mohammed; Cativo, Eder H.; Visco, Ferdinand; Mushiyev, Savi; Pekler, Gerald

doi:10.1016/j.ijcard.2018.08.058

Cited by 11 publications

(23 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…e use of cocaine was confirmed by self-reported history and positive urine toxicology in six studies [10,12,16,18,20,21], positive urine toxicology in another five [11,13,15,17,19], and only self-reported in one study [14]. Carvedilol (combined beta1,2 and alpha blocker) alone was used in five studies [11,12,14,15,21], carvedilol, labetalol (combined beta1,2 and alpha blocker), bisoprolol, metoprolol tartrate, and metoprolol succinate were used in one study [16], and carvedilol and metoprolol succinate were used in two studies [18,20]. Both cardioselective and noncardioselective beta blockers (not specified) were used in one study [13], and three studies did not specify the type of beta blockers used [10,17,19].…”

Section: Resultsmentioning

confidence: 92%

“…Of the 12 articles reviewed, ten were retrospective studies involving a review of medical records [10,11,13,[15][16][17][18][19][20][21], one study was a case series of four patients [12], and one was a case report [14]. e sample size ranged from 1 to 503 patients with a median of 111. e total number of patients was 1994.…”

Section: Resultsmentioning

confidence: 99%

“…Both cardioselective and noncardioselective beta blockers (not specified) were used in one study [13], and three studies did not specify the type of beta blockers used [10,17,19]. e primary outcomes were readmission (all cause and heart failure related) in nine studies [10-13, 15-17, 19, 20], mortality in seven studies [10,11,13,[15][16][17]19], LVEF improvement in six studies [12-14, 17, 18, 20], NYHA functional class in three studies [12,18,20], and major adverse cardiovascular events (MACEs) in four studies [16,18,20,21] as shown in Table 2.…”

Section: Resultsmentioning

confidence: 99%

“…Nine studies provided either partial or complete data on statistical measures [10,13,[15][16][17][18][19][20][21], and one study did not report any statistical outcomes [11]. Statistical analysis was not applicable for two studies (case series and case report) [12,14].…”

Section: Resultsmentioning

confidence: 99%

“…Statistical analysis was not applicable for two studies (case series and case report) [12,14]. e risk of bias within the studies was calculated using multivariate analysis in four studies [16,[19][20][21]. Due to the retrospective nature of studies, variance in analytic approaches, and incomplete statistical data (also because of only abstract publication), formal synthesis was not possible and risk of bias across studies could not be determined.…”

Section: Resultsmentioning

confidence: 99%

See 4 more Smart Citations

Beta Blocker Therapy in Heart Failure Patients with Active Cocaine Use: A Systematic Review

Mann

Bhandohal

Saeed

et al. 2020

Cardiology Research and Practice

Self Cite

View full text Add to dashboard Cite

Background. Cocaine use is associated with multiple cardiovascular complications including heart failure. The use of different types of beta blockers in heart failure patients with active cocaine use is still a matter of debate. In this review, our objective is to systematically review the available literature regarding the use of beta blockers in the treatment of heart failure patients with concurrent cocaine use. Methods. PubMed, EMBASE, Web of Science, and Clinical Trials.gov were searched from inception to March 2019 using the Medical Subject Headings (MeSH) terms “cocaine”, “heart failure”, “beta blocker,” and “cardiomyopathy”. Only studies containing the outcomes of heart failure patients with active cocaine use who were treated with beta blockers were included. Results. The search resulted in 2072 articles out of which 12 were finally included in the review. A total number of participants were 1994 with a median sample size of 111. Most of the studies were retrospective in nature with Oxford Centre for Evidence-Based Medicine (OCEBM) Levels of Evidence from 3 to 5. The main primary outcomes included readmission rates, mortality, left ventricular ejection fraction (LVEF) improvement, New York Heart Association (NYHA) functional class, and major adverse cardiovascular events (MACEs). In the studies analyzed, beta blockers were found to have either a beneficial or a neutral effect on primary outcomes in heart failure patients with active cocaine use. Conclusion. The use of beta blocker therapy appears to be safe and beneficial in heart failure patients with active cocaine use, although the evidence is not robust. Furthermore, large-scale studies are required to confirm this finding.

show abstract

Section: Resultsmentioning

confidence: 92%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 3 more Smart Citations

Beta Blocker Therapy in Heart Failure Patients with Active Cocaine Use: A Systematic Review

Mann

Bhandohal

Saeed

et al. 2020

Cardiology Research and Practice

Self Cite

View full text Add to dashboard Cite

show abstract

Opposing forces of cardiogenic shock: left ventricular outflow obstruction, severe mitral regurgitation, and left ventricular dysfunction in Takotsubo cardiomyopathy

et al. 2022

View full text Add to dashboard Cite

Rates of stress (Takotsubo) cardiomyopathy have increased during the coronavirus pandemic due to social stressors, even in patients who are not infected with the virus. At times, Takotsubo cardiomyopathy (TC) may present as cardiogenic shock. Herein, we present a case during the pandemic of shock from TC secondary to left ventricular outflow tract obstruction (LVOTO), mitral regurgitation (MR), and left ventricular (LV) dysfunction. The contrasting management strategy of LVOTO, MR, and LV failure was cause for clinical challenge, and we highlight the balance of treating these opposing forces.

show abstract